OTCMKTS:PRVCF PreveCeutical Medical (PRVCF) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free PRVCF Stock Alerts $0.01 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0147▼$0.014750-Day Range$0.0113▼$0.019052-Week Range$0.01▼$0.03Volume20,000 shsAverage Volume58,074 shsMarket Capitalization$7.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get PreveCeutical Medical alerts: Email Address Ad Prosper Trading AcademyThis AI Trade Machine Made 1,729%* (With 89% Wins)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?Click Here To Get Your Free Copy About PreveCeutical Medical Stock (OTCMKTS:PRVCF)PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.Read More PRVCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRVCF Stock News HeadlinesMarch 15, 2024 | morningstar.comPreveCeutical Medical Inc PRVCFSeptember 18, 2023 | finance.yahoo.comPreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD ApplicationApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.September 12, 2023 | finance.yahoo.comPreveCeutical Showcases Dynamic Evolution in AI StrategyJune 28, 2023 | finance.yahoo.comPreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses ThereofMay 30, 2023 | finance.yahoo.comPreveCeutical Medical - Sol-Gel and Uses thereof Patent UpdateApril 24, 2023 | finance.yahoo.comPreveCeutical Medical Launches Clinical Artificial Intelligence DivisionApril 20, 2023 | finance.yahoo.comPreveCeutical Medical Announces Live Interactive Q&A Video ConferenceApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 4, 2023 | finance.yahoo.comPreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe PainMarch 20, 2023 | finance.yahoo.comPreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure CommitteeFebruary 23, 2023 | seekingalpha.comPRVCF PreveCeutical Medical Inc.February 21, 2023 | finance.yahoo.comAppointment of C. Evan Ballantyne to PreveCeutical's Board of DirectorsFebruary 7, 2023 | finance.yahoo.comPreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical DevelopmentJanuary 14, 2023 | msn.comPreveCeutical, Endosane team up for sol-gel tech use in cannabis therapyJanuary 12, 2023 | finance.yahoo.comPreveCeutical Enters into License Option Agreement with Endosane PharmaceuticalsJanuary 9, 2023 | finance.yahoo.comPreveCeutical Signs Intercompany Sol-Gel License AgreementNovember 23, 2022 | finance.yahoo.comThe Power Play by The Market Herald Releases New Interviews with Eloro Resources, Prospera, Datametrex, Gamelancer Media, Infinity Stone Ventures and PreveCeutical Medical Discussing Their Latest NewsNovember 21, 2022 | finance.yahoo.comPreveCeutical Files Application for D-amino Acid PeptidesNovember 12, 2022 | finanznachrichten.dePreveCeutical Medical Inc.: PreveCeutical Announces Conversion of DebtNovember 12, 2022 | finance.yahoo.comPreveCeutical Announces Conversion of DebtOctober 20, 2022 | finance.yahoo.comAppointment of Kathleen Rotika to PreveCeutical's Board of DirectorsSeptember 17, 2022 | finance.yahoo.comPreveCeutical Announces Resignation of Board of Director MemberSeptember 6, 2022 | finance.yahoo.comAppointment of Sachin Nanavati to PreveCeutical's Board of DirectorsMay 27, 2022 | finance.yahoo.comPreveCeutical Announces Change in Directors and Investor Awareness ServicesMay 9, 2022 | finance.yahoo.comArticle Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of PharmacologyNovember 29, 2021 | finance.yahoo.comPreveCeutical Files International Patent Application for Sol-Gel Cannabinoid Formulation for Antiviral UseSee More Headlines Receive PRVCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PreveCeutical Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:PRVCF CUSIPN/A CIKN/A Webwww.preveceutical.com Phone(604) 416-7777Fax778-945-6290EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,140,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-272.69% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-1.47Miscellaneous Outstanding Shares535,303,000Free FloatN/AMarket Cap$7.87 million OptionableNot Optionable Beta0.73 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Stephen Van Deventer (Age 55)Chairman, CEO & CFO Comp: $90.68kDr. Makarand Jawadekar Ph.D. (Age 73)Chief Science Officer, President & Director Comp: $55.35kMr. Shawn SadlerHead of Artificial IntelligenceKey CompetitorsMDxHealthOTCMKTS:MXDHFBZAMOTCMKTS:BZAMFPoxelOTCMKTS:PXXLFNicoxOTCMKTS:NICXFElse NutritionOTCMKTS:BABYFView All Competitors PRVCF Stock Analysis - Frequently Asked Questions How have PRVCF shares performed in 2024? PreveCeutical Medical's stock was trading at $0.0181 on January 1st, 2024. Since then, PRVCF shares have decreased by 18.8% and is now trading at $0.0147. View the best growth stocks for 2024 here. How do I buy shares of PreveCeutical Medical? Shares of PRVCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PRVCF) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PreveCeutical Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
